Companies’ precision medicine approach has potential to increase clinical trial success rates
News
Poolbeg progress oral vaccine programme
Poolbeg’s platform will possess the capability to generate vaccines for a wide range of diseases
Alchemab Therapeutics reveals Alzheimer’s candidate
ATLX-1088 is regarded as a possible first-in-class human antibody targeting CD33 – a cell surface protein
Delix Therapeutics completes dose study for DLX-001
During research there were not any clinically-relevant adverse events or psychotomimetic effects
Avacta announces AVA6000 dose escalation results
Candidate is a cancer therapy that has been chemically modified with Avacta’s pre|CISION platform
FluoGuide announces head and neck cancer therapy results
The treatment is administered intravenously prior to surgery, lighting up cancer during surgery
BioSenic to deliver news on copper-arsenic trioxide combination
Immunological disorder therapy data to be shared at International Conference on Redox Medicine
Greener NHS and NHS Innovation Accelerator collaborate
Partnership will help NHS to prepare for fundamental change, including reducing carbon emissions
Anoat Therapeutics receives cystic fibrosis funding boost
Vital financing will be used to develop novel therapies for condition with high unmet medical need
Rosemont acquires Lucis Pharma to boost portfolio
Company will gain access to a considerable pipeline of liquid products covering various disease areas
genedrive awarded test kit grant
DEVOTE grant will allow acute care patient access and a supporting infrastructure for the company
Positive profile for Enterome’s lymphoma candidate
EO2463 is an experimental treatment for indolent non-Hodgkin B cell lymphoma
Birmingham University reveals antimicrobial discovery
Researchers show silver retains antimicrobial activity for longer when it is infused into bioactive glass
PharmaTimes Communications Awards 2023 – Everything you need to know!
Find out more about the PharmaTimes Communications Awards 2023 – key dates, categories and which charity we have partnered with this year!
Owlstone Medical delivers breath biopsy test data
Preliminary data has shown excellent safety, while also demonstrating proof of mechanism
